2018 Pharmaceutical Companies Pharmaceutical Manufacturing 
European Pharmaceutical Review
JULY 12, 2022
Microbes developing resistance to disinfectants is a major emerging problem in pharmaceutical manufacturing cleanrooms and, if left unchecked, could present a threat to drug quality and, therefore, human health. Microbial resistance is one of the factors responsible for such failings.
Pharmaceutical Technology
NOVEMBER 21, 2022
However, despite this significant market share, the Japanese market is likely to become a less attractive market for international pharmaceutical companies based on recent findings from the Office of Pharmaceutical Industry Research (OPIR). Other reasons include lower sales demand and high investment costs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
NOVEMBER 21, 2022
However, despite this significant market share, the Japanese market is likely to become a less attractive market for international pharmaceutical companies based on recent findings from the Office of Pharmaceutical Industry Research (OPIR). Other reasons include lower sales demand and high investment costs.
pharmaphorum
DECEMBER 28, 2022
In 2018, over 60% of all new molecular entities came from smaller biopharma firms, compared with just over 30% in 2009. So, how do smaller pharmaceutical companies at the cutting edge get ready for their acquisition milestone, so they maximise their value and attractiveness?
European Pharmaceutical Review
DECEMBER 21, 2022
2 However, most of these efforts relating to catalysis, 3 process waste metrics, 4 lifecycle assessments, 5 pharmaceuticals in the environment 6 and the phase out of substances of concern 7 mainly mitigate the consequences of pharmaceutical manufacturing. Environ Sci Technol 2018, 52, 4, 1725–1734 [link].
European Pharmaceutical Review
AUGUST 17, 2022
We are the largest life sciences coalition bringing together various life science industry representatives,” including over 100 biotech, diagnostics, generics and research-based pharmaceutical companies and associations, to drive collaborative approaches and measure the life-sciences’ industry progress to curb AMR. 2019;15(3):312-319.
pharmaphorum
AUGUST 25, 2020
We carried out opinion research on the Code in 2018, and found that the interviewees associated positive changes in industry practice with developments in the Code. That has contributed to improving the perception of the industry and of HCPs. Through alignment we can make these processes more seamless.
Expert insights. Personalized for you.
111 
Let's personalize your content